S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:BCAB

BioAtla Competitors

$53.10
-0.93 (-1.72 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$51.73
Now: $53.10
$55.82
50-Day Range
$38.25
MA: $47.31
$56.04
52-Week Range
$27.15
Now: $53.10
$58.40
Volume339,600 shs
Average Volume234,105 shs
Market Capitalization$1.70 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

BioAtla (NASDAQ:BCAB) Vs. SANA, ABCM, SEER, CGEM, VOR, and SBTX

Should you be buying BCAB stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to BioAtla, including Sana Biotechnology (SANA), Abcam (ABCM), Seer (SEER), Cullinan Management (CGEM), Vor Biopharma (VOR), and Silverback Therapeutics (SBTX).

Sana Biotechnology (NASDAQ:SANA) and BioAtla (NASDAQ:BCAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Valuation & Earnings

This table compares Sana Biotechnology and BioAtla's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Sana Biotechnology and BioAtla, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sana Biotechnology0000N/A
BioAtla00403.00

BioAtla has a consensus price target of $48.00, indicating a potential downside of 9.60%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Sana Biotechnology.

Profitability

This table compares Sana Biotechnology and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sana BiotechnologyN/AN/AN/A
BioAtlaN/AN/AN/A

Summary

BioAtla beats Sana Biotechnology on 2 of the 2 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and BioAtla (NASDAQ:BCAB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Abcam and BioAtla, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam02302.60
BioAtla00403.00

Abcam currently has a consensus target price of $22.3333, suggesting a potential downside of 6.28%. BioAtla has a consensus target price of $48.00, suggesting a potential downside of 9.60%. Given Abcam's higher possible upside, analysts plainly believe Abcam is more favorable than BioAtla.

Profitability

This table compares Abcam and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
BioAtlaN/AN/AN/A

Valuation & Earnings

This table compares Abcam and BioAtla's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Summary

BioAtla beats Abcam on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Seer (NASDAQ:SEER) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Earnings and Valuation

This table compares BioAtla and Seer's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Profitability

This table compares BioAtla and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
SeerN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for BioAtla and Seer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Seer02202.50

BioAtla currently has a consensus target price of $48.00, suggesting a potential downside of 9.60%. Seer has a consensus target price of $69.6667, suggesting a potential upside of 44.45%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than BioAtla.

Summary

BioAtla beats Seer on 2 of the 3 factors compared between the two stocks.

Cullinan Management (NASDAQ:CGEM) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cullinan Management and BioAtla, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Management01302.75
BioAtla00403.00

Cullinan Management currently has a consensus price target of $48.00, suggesting a potential upside of 18.75%. BioAtla has a consensus price target of $48.00, suggesting a potential downside of 9.60%. Given Cullinan Management's higher probable upside, equities analysts clearly believe Cullinan Management is more favorable than BioAtla.

Earnings & Valuation

This table compares Cullinan Management and BioAtla's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan ManagementN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Profitability

This table compares Cullinan Management and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan ManagementN/AN/AN/A
BioAtlaN/AN/AN/A

Summary

BioAtla beats Cullinan Management on 2 of the 3 factors compared between the two stocks.

Vor Biopharma (NYSE:VOR) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.

Valuation & Earnings

This table compares Vor Biopharma and BioAtla's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vor BiopharmaN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Vor Biopharma and BioAtla, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vor Biopharma0000N/A
BioAtla00403.00

BioAtla has a consensus price target of $48.00, indicating a potential downside of 9.60%. Given BioAtla's higher possible upside, analysts plainly believe BioAtla is more favorable than Vor Biopharma.

Profitability

This table compares Vor Biopharma and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vor BiopharmaN/AN/AN/A
BioAtlaN/AN/AN/A

Summary

BioAtla beats Vor Biopharma on 2 of the 2 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Profitability

This table compares BioAtla and Silverback Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioAtlaN/AN/AN/A
Silverback TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for BioAtla and Silverback Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioAtla00403.00
Silverback Therapeutics00403.00

BioAtla currently has a consensus price target of $48.00, suggesting a potential downside of 9.60%. Silverback Therapeutics has a consensus price target of $46.25, suggesting a potential downside of 3.77%. Given Silverback Therapeutics' higher possible upside, analysts clearly believe Silverback Therapeutics is more favorable than BioAtla.

Valuation and Earnings

This table compares BioAtla and Silverback Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtlaN/AN/AN/AN/AN/A
Silverback TherapeuticsN/AN/AN/AN/AN/A

Summary

Silverback Therapeutics beats BioAtla on 1 of the 1 factors compared between the two stocks.


BioAtla Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SANA
Sana Biotechnology
1.0$30.74-4.3%$5.65 billionN/A0.00Gap Down
Abcam logo
ABCM
Abcam
1.1$23.83-4.1%$5.40 billionN/A0.00Decrease in Short Interest
SEER
Seer
1.3$48.23-5.3%$2.94 billionN/A0.00Decrease in Short Interest
Gap Down
CGEM
Cullinan Management
1.2$40.42-5.6%$1.67 billionN/A0.00
VOR
Vor Biopharma
0.3$44.96-20.3%$1.60 billionN/A0.00Gap Down
SBTX
Silverback Therapeutics
1.8$48.06-3.2%$1.59 billionN/A0.00Increase in Short Interest
GRCL
Gracell Biotechnologies
1.7$22.73-3.4%$1.49 billionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.6$41.58-0.5%$1.46 billionN/A0.00Upcoming Earnings
KNTE
Kinnate Biopharma
2.0$33.43-0.9%$1.39 billionN/A0.00Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$35.61-6.1%$1.39 billionN/A0.00
PHVS
Pharvaris
0.0$37.99-5.6%$1.21 billionN/A0.00Gap Up
FDMT
4D Molecular Therapeutics
0.9$41.98-3.1%$1.06 billionN/A0.00Increase in Short Interest
SGTX
Sigilon Therapeutics
1.9$26.60-2.7%$803.05 millionN/A0.00Increase in Short Interest
Inventiva logo
IVA
Inventiva
1.7$15.00-3.6%$575.90 millionN/A0.00High Trading Volume
NEXI
NexImmune
0.3$25.91-0.5%$558.39 millionN/A0.00
TERN
Terns Pharmaceuticals
1.3$22.65-0.1%$542.97 millionN/A0.00
LABP
Landos Biopharma
1.3$13.48-3.6%$527.92 millionN/A0.00
ANGN
Angion Biomedica
0.0$17.34-23.4%$498.02 millionN/A0.00
SNSE
Sensei Biotherapeutics
0.3$16.50-1.3%$487.71 millionN/A0.00Gap Down
DBTX
Decibel Therapeutics
0.3$18.78-0.4%$456.39 millionN/A0.00Gap Up
Unity Biotechnology logo
UBX
Unity Biotechnology
1.2$6.81-0.4%$360.34 millionN/A-3.62Gap Up
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$8.93-7.4%$321.32 millionN/A-3.53
GMTX
FS Development
0.0$15.20-1.3%$236.13 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$13.44-0.4%$225.91 millionN/A0.00Decrease in Short Interest
NUVB
Nuvation Bio
0.0$10.03-3.7%$185.11 millionN/A0.00
ANVS
Annovis Bio
0.0$25.57-1.1%$176.59 millionN/A0.00
VINC
Vincerx Pharma
1.0$19.30-2.1%$158.36 millionN/A0.00Increase in Short Interest
LGVN
Longeveron
0.3$8.00-8.0%$149.66 millionN/A0.00
EVAX
Evaxion Biotech A/S
0.0$6.98-6.2%$134.01 millionN/A0.00
IKT
Inhibikase Therapeutics
0.0$6.70-5.8%$67.34 millionN/A0.00
VIRI
Virios Therapeutics
1.3$6.19-2.4%$48.48 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$6.11-0.2%$41.28 millionN/A0.00Gap Down
ADTX
ADiTx Therapeutics
1.0$3.03-3.6%$0.00N/A0.00Decrease in Short Interest
CBDC
Apotheca Biosciences
0.4$0.03-33.3%$0.00N/A0.00High Trading Volume
Gap Up
CDMOP
Avid Bioservices
0.3$29.60-1.7%$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Down
BCTX
BriaCell Therapeutics
0.0$3.40-8.8%$0.00N/A0.00High Trading Volume
SCPS
Scopus BioPharma
1.4$9.27-5.3%$0.00N/A0.00Decrease in Short Interest
Gap Down
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.